Patents Assigned to Rheinische Friedrich-Wilhelms-Universitat
-
Publication number: 20150275217Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.Type: ApplicationFiled: March 27, 2015Publication date: October 1, 2015Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONNInventors: Marion GOLDECK, Jasper VAN DEN BOORN, János LUDWIG, Christine SCHUBERTH-WAGNER
-
Patent number: 9103819Abstract: The present invention relates to a tumor cell of the peripheral zone of a tumor and methods of providing such a tumor cell. Further provided is a method for identifying a molecular marker diagnostic for an infiltrative cancer, an antibody, which specifically binds to such molecular marker, a method for identifying a therapeutic compound effective against a metastatic/infiltrative cancer disease and the use of a tumor cell according to the invention.Type: GrantFiled: September 9, 2009Date of Patent: August 11, 2015Assignee: Rheinische Friedrich-Wilhelms-Universität BonnInventors: Björn Scheffler, Matthias Simon, Oliver Brüstle, Ulrich Johannes Herrlinger, Martin Glas
-
Patent number: 9011862Abstract: The present invention relates to a method for identifying an inhibitor of the aggregation of amyloid-? peptide (A?), comprising the steps of a) contacting at least one A? -peptide and/or the nitrated forms thereof with at least one candidate inhibitor that potentially specifically binds to a region in said A? -peptide capable of being nitrated, and b) detecting said inhibitor specifically binding to said region in said A? -peptide through detecting a lack of or a reduced aggregation of said at least one A? -peptide. The present invention is further directed at improved methods for treating neuronal degradation and particularly Alzheimer's disease, based on said inhibitor. The present invention is further directed at methods for diagnosing the aggregation of A? -peptide in the context of neuronal degradation and particularly Alzheimer's disease.Type: GrantFiled: July 12, 2010Date of Patent: April 21, 2015Assignee: Rheinische Friedrich-Wilhelms-Universität BonnInventors: Michael Thomas Heneka, Markus Peter Kummer
-
Publication number: 20150057161Abstract: The invention is based on the finding of specific surface markers for M1-like (classically activated) and M2-like (alternatively activated) macrophages and provides for a method for the identification, characterization and isolation of M1-like and M2-like macrophages based on the abundance of said surface markers and for means for performing such method.Type: ApplicationFiled: March 13, 2013Publication date: February 26, 2015Applicants: BECTON DICKINSON AND COMPANY, RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT-BONNInventors: Joachim Schultze, Michael Mallmann
-
Patent number: 8846645Abstract: The present invention relates to compounds according to general formula (I), pharmaceutical compositions comprising compounds according to general formula (I) and the use of the compounds for the treatment of a bacterial infection, particularly for use as an antibiotic.Type: GrantFiled: December 13, 2011Date of Patent: September 30, 2014Assignees: Rheinische Friedrich-Wilhelms Universität Bonn, Universität KonstanzInventors: Günter Mayer, Christina Elsbeth Luense, Valentin Wittmann, Magnus S. Schmidt
-
Publication number: 20140288019Abstract: A phosphorylated A2A receptor agonist providing agonist properties on the A2A receptor after dephosphorylation the phosphorylated A2A receptor agonist comprises a ribosyl moiety and a purine moiety and being phosphorylated at the 5?-position of the ribose moiety except adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (ATP), a medicament containing the compound of the invention including ADP and the use of the compound of the invention including ATP and ADP for several medical indications e.g. inflammatory events. In particular, compounds of formula (I) are also disclosed.Type: ApplicationFiled: December 16, 2013Publication date: September 25, 2014Applicants: Rheinische Friedrich-Wilhelms-Universitat Bonn, Heinrich-Heine- Universität DüsseldorfInventors: Jurgen SCHRADER, Christa Muller, Ali El-Tayeb, Jamshed Iqbal
-
Patent number: 8815503Abstract: The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IL-12-inducing activity to a single-stranded RNA oligonucleotide. The present invention also provides single-stranded RNA oligonucleotides, including antisense RNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for therapeutic purposes.Type: GrantFiled: September 14, 2006Date of Patent: August 26, 2014Assignee: Rheinische Friedrich-Wilhelms-Universitat BonnInventors: Gunther Hartmann, Veit Hornung
-
Publication number: 20140066409Abstract: The present invention relates to compounds according to general formula (I), pharmaceutical compositions comprising compounds according to general formula (I) and the use of the compounds for the treatment of a bacterial infection, particularly for use as an antibiotic.Type: ApplicationFiled: December 13, 2011Publication date: March 6, 2014Applicants: UNIVERSITÄT KONSTANZ, RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONNInventors: Günter Mayer, Christina Elsbeth Luense, Valentin Wittmann, Magnus S. Schmidt
-
Patent number: 8623593Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.Type: GrantFiled: March 4, 2013Date of Patent: January 7, 2014Assignee: Rheinische Friedrich-Wilhelms-Universität BonnInventors: Evi Kostenis, Andreas Spinrath, Stephanie Hennen, Lucas Peters, Christa E. Muller, Rhalid Akkari, Younis Baqi, Kirsten Ritter
-
Publication number: 20130344486Abstract: The present invention relates to methods of diagnosing a breast carcinoma, determining the prognosis of a patient diagnosed with breast carcinoma and determining the efficacy of a treatment regimen of breast carcinoma in a patient, using Calponin-h2 and/or CALML 5 as markers. Furthermore, the invention relates to a kit and a marker panel for use in these methods.Type: ApplicationFiled: February 28, 2012Publication date: December 26, 2013Applicant: Rheinische Friedrich-Wilhelms-Universitat BonnInventors: Manuel Debald, Gisela Walgenbach-brunagel
-
Publication number: 20130338374Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.Type: ApplicationFiled: March 4, 2013Publication date: December 19, 2013Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONNInventors: Evi Kostenis, Andreas Spinrath, Stephanie Hennen, Lucas Peters, Christa E. Muller, Rhalid Akkari, Younis Baqi, Kirsten Ritter
-
Publication number: 20130158093Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.Type: ApplicationFiled: February 25, 2013Publication date: June 20, 2013Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONNInventor: Rheinische Friedrich-Wilhelms-Universität Bonn
-
Patent number: 8404436Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.Type: GrantFiled: February 28, 2012Date of Patent: March 26, 2013Assignee: Rheinische Friedrich-Wilhelms-Universitat BonnInventors: Evi Kostenis, Andreas Spinrath, Stephanie Hennen, Lucas Peters, Christa E. Muller, Rhalid Akkari, Younis Baqi, Kirsten Ritter
-
Publication number: 20130059899Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.Type: ApplicationFiled: February 28, 2012Publication date: March 7, 2013Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONNInventors: Evi Kostenis, Andreas Spinrath, Stephanie Hennen, Lucas Peters, Christa E. Müller, Rhalid Akkari, Younis Baqi, Kirsten Ritter
-
Patent number: 8163788Abstract: The invention relates to a pharmaceutical composition and the use thereof, wherein the pharmaceutical composition contains compounds selected from a group of general formulas (5), (6), (7) and (8) and/or enantiomers, diastereomers or the pharmaceutically acceptable salts thereof. The pharmaceutical composition is used for treating autoimmune and tumoral diseases and/or for immunosuppresion.Type: GrantFiled: November 18, 2005Date of Patent: April 24, 2012Assignee: Rheinische Friedrich-Wilhelms Universitat BonnInventors: Michael Famulok, Waldemar Kolanus, Markus Hafner, Imke Grune, Barbara Tappertzhofen, Mirko Theis
-
Publication number: 20110312893Abstract: The invention relates to a method for isolating neural cells using tenascin-R compounds, tenascin-R fragments particularly suited for said method and tenascin-R fusion proteins, to recombinant preparation of said tenascin-R compounds, and to a kit for carrying out said method and to the use of said method for preparing high-purity neural cell populations. The invention further relates to antibodies suitable for detecting and isolating tenascin-R compounds.Type: ApplicationFiled: September 16, 2009Publication date: December 22, 2011Applicant: RHEINISCHE -FRIEDRICH-WILHELMS-UNIVERSITÄT BONNInventors: Penka Pesheva, Rainer Probstmeier
-
Publication number: 20110260814Abstract: Disclosed is a device for generating a uniform magnetic field and to an optimization method for magnetic fields in a sample space, the method providing specifications for producing such a device. The device comprises at least one field coil for generating the magnetic field and the turns of the field coil are continuously wound around the sample space and the turn diameter of the field coil changes continuously at least in a portion of the field coil along the longitudinal axis of the sample space. To this end, the correction of non-uniformities in the magnetic field caused by the finite length of the field coil is distributed over the entire field coil. In this way, the device can be implemented more easily and precisely than with the correction coils used according to the prior art for correcting non-uniformities.Type: ApplicationFiled: November 30, 2009Publication date: October 27, 2011Applicants: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN, FORSCHUNGSZENTRUM JÜLICH GMBHInventors: Andrea Raccanelli, Rolf Krause
-
Publication number: 20110224279Abstract: The present invention relates to a nucleic acid molecule and a pharmaceutical or diagnostic composition for the therapeutic and/or prophylactic treatment or diagnosis of cancer and/or metastasis thereof, comprising a nucleic acid molecule, or an amino acid sequence related to Trim71 and/or its mammalian and non mammalian orthologs and/or a nucleic acid sequence of the gene encoding for Trim71 and/or its mammalian and non mammalian orthologs.Type: ApplicationFiled: February 27, 2009Publication date: September 15, 2011Applicant: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITATInventors: Waldemar Kolanus, Michael Karl Hoch, Joachim L. Schultze, Birgit Loeer
-
Publication number: 20110159012Abstract: The invention relates to a process for isolating neural cells using tenascin-R compounds, tenascin-R fragments and tenascin-R fusion proteins that are particularly suitable for such process, the recombinant preparation of such tenascin-R compounds, and a kit for performing this process, and the use of the process for preparing highly pure neural cell populations. The invention further relates to antibodies suitable for the detection and isolation of tenascin-R compounds.Type: ApplicationFiled: December 16, 2005Publication date: June 30, 2011Applicant: RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONNInventor: Penka Pesheva
-
Publication number: 20110104691Abstract: The present invention relates to methods for testing for a predisposition or presence of androgenetic alopecia comprising testing a sample obtained from a prospective patient or from a person suspected of carrying a predisposition for androgenetic alopecia. The invention also relates to a genetic marker for androgenetic alopecia characterised in that the genetic marker is located in a chromosomal region of human chromosome 20p11 and wherein the genetic marker is selected from the group consisting of a single nucleotide polymorphism (SNP), variable number of tandem repeat (VNTR), microsatellites or short tandem repeats (STR). Further, the invention relates to a diagnostic composition for the detection of androgenetic alopecia or a predisposition therefore as well as to a kit.Type: ApplicationFiled: April 7, 2009Publication date: May 5, 2011Applicants: LIFE & BRAIN GMBH, HEINRICH-HEIN-UNIVERSITAT DUSSELDORF, RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITATInventors: Markus M. Nöthen, Felix F. Brockschmidt, Axel Hillmer, Roland Kruse